CD274 and non-small cell lung carcinoma: Finally, the programmed death‐ligand 1 (PD‐L1) assessment evaluated by immunohistochemistry (IHC) as tumor proportion score (TPS), is one of the required indicators to select NSCLC patients for immune checkpoint inhibitor therapy.11